Human Intervention Study of Egg Protein Derivative on Cardiovascular Risk (CardiProtein)

University College Cork (UCC)

Status: Completed

Conditions: Hypertension

Treatments: Dietary Supplement: Egg albumin-derived peptide

Study type: Interventional

Funder types: Other

Identifiers

NCT02223169

ECFP7-312090

Details and patient eligibility

About

Heart disease and stroke are the most common cause of death in Ireland today.One of the main risk factors for heart disease and stroke is high blood pressure or hypertension. Research has found that certain specific proteins or peptides found in foods such as dairy, meat, fish and eggs may promote heart health reducing blood pressure in adults with hypertension. The aim of this study is to investigate the potential beneficial effects egg peptides may have on heart health, in particular, effects on blood pressure.

Full description

Poor dietary habits of Irish adults has been accompanied by epidemics of obesity and metabolic disorders such as type II diabetes leading to a substantial predicted increase in the prevalence of chronic diseases such as cardiovascular disease.Hypertension is a major contributing factor to the development of cardiovascular and metabolic diseases. Dietary factors play a significant role in the prevention and/or treatment of hypertension and therefore the development of foods with antihypertensive properties could prove beneficial.

Enrollment: 69 patients

Sex: All

Ages: 50 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Male and female
• Non-diabetic
• Aged 50-65
• BMI 25-35kg/m²
• Mild hypertensive: Blood pressure 130-149 mmHg

Exclusion criteria

• Current smoker
• Diagnosed hypertensive
• History of cardiovascular disease
• Diabetic
• Chronic kidney disease
• Gastrointestinal disease
• Currently on anti-hypertensive medications
• Allergic to eggs

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

69 participants in 2 patient groups, including a placebo group

Egg albumin-derived peptide

Experimental group

Description:

Each participant will consume 1 sachet of Egg albumin-derived peptide (3 g) each day mixed with a fruit juice drink for 42 days.

Treatment:

Dietary Supplement: Egg albumin-derived peptide

Placebo

Placebo Comparator group

Description:

Participants will consume one sachet of the placebo mixed with a fruit juice drink that will appear and taste similar to the albumin derived peptide sachet.

Treatment:

Dietary Supplement: Egg albumin-derived peptide